Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Swedish Orphan Biovitrum ABSWOBY +4.56%67 3-Year Book Growth Rate is 8.40% as of Jun. 2026, which is 38% below its 10-year median of 13.60. GuruFocus rates SWOBY with a GF Scoreâ„¢ of 67/100 and a GF Valueâ„¢ of $18.51 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 909 Drug Manufacturers companies, Swedish Orphan Biovitrum AB ranks better than 63.48% on this metric.
During the past 12 months, Swedish Orphan Biovitrum AB's average Book Value per Share Growth Rate was 7.40% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 8.40% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 12.30% per year.
During the past 10 years, the average Book Value per Share Growth Rate was 23.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Swedish Orphan Biovitrum AB was 42.30% per year. The lowest was -13.00% per year. And the median was 13.60% per year.
Swedish Orphan Biovitrum AB (OTCPK:SWOBY) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Swedish Orphan Biovitrum AB 3-Year Book Growth Rate Related Terms
SWOBY vs ZTS: 3-Year Book Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB 3-Year Book Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's 3-Year Book Growth Rate falls into.
Swedish Orphan Biovitrum AB 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 8.40% mean?
Swedish Orphan Biovitrum AB (SWOBY) has a 3-Year Book Growth Rate of 8.40% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Swedish Orphan Biovitrum AB and its competitors. This is 38% below median its historical median of 13.60. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #332 out of 909 companies in the Drug Manufacturers industry, placing it in the top 36.5%.
Is Swedish Orphan Biovitrum AB's 3-Year Book Growth Rate too high?
Swedish Orphan Biovitrum AB's current 3-Year Book Growth Rate of 8.40% is 38% below median its 10-year median of 13.60. The Drug Manufacturers industry median 3-Year Book Growth Rate is 4.80. Swedish Orphan Biovitrum AB's value of 8.40% is 75% above this industry median. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #332 out of 909 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Swedish Orphan Biovitrum AB has a GF Scoreâ„¢ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's 3-Year Book Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #332 out of 909 companies for 3-Year Book Growth Rate. This puts Swedish Orphan Biovitrum AB in the upper half of its industry. The industry median 3-Year Book Growth Rate is 4.80. Swedish Orphan Biovitrum AB's value of 8.40% is 75% above this benchmark. While the company's 10-year median is 13.60 vs. the industry median of 4.80, Swedish Orphan Biovitrum AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Drug Manufacturers company?
The median 3-Year Book Growth Rate among Drug Manufacturers companies is 4.80, based on 909 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Swedish Orphan Biovitrum AB's current 3-Year Book Growth Rate of 8.40% is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Swedish Orphan Biovitrum AB and its competitors. For the Drug Manufacturers industry, the median 3-Year Book Growth Rate is 4.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Swedish Orphan Biovitrum AB's current 3-Year Book Growth Rate is 8.40%, which is 38% below median its own 10-year median of 13.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (SWOBY) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.51, compared to a current price of $24.31 — trading 31.3% above its estimated fair value. The current 3-Year Book Growth Rate is 8.40%, which is 38% below median its 10-year median of 13.60 and 75% above the Drug Manufacturers industry median of 4.80. Swedish Orphan Biovitrum AB's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (SWOBY), the current 3-Year Book Growth Rate is 8.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Swedish Orphan Biovitrum AB (SWOBY) Overvalued in 2026?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued.
The current stock price of $24.31 is trading 31.3% above its estimated GF Value™ of $18.51.
GuruFocus considers Swedish Orphan Biovitrum AB to be Significantly Overvalued.
Key valuation signals for SWOBY:
3-Year Book Growth Rate: 8.40% (38% below median its 10-year median of 13.60)
GF Value™: $18.51 vs. price of $24.31 (31.3% above fair value)
Industry Position: 75% above the Drug Manufacturers median (#332 of 909)
No single metric tells the full story. See the SWOBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
67GF Score
Get the complete analysis for SWOBY
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SWOBY has been successfully added to your 
